Hematologic Oncology

The FDA approved a new option in resectable gastric cancer, and a new agent is under priority review in mantle cell lymphoma.

The NCCN guidelines for AML have been updated to include ziftomenib as a category 2A recommendation for NPM1-mutant, relapsed/refractory AML management.

The FDA approved 5 therapeutic options spanning lung cancer, urothelial cancer, NF1-associated PNs, and AL amyloidosis.

Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.

The FDA has granted traditional approval to daratumumab and hyaluronidase-fihj with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed light chain amyloidosis.

The European Commission has approved subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma.

Liquid biopsy offers a revolutionary approach for detecting relapse in patients with AML post stem cell transplant, potentially enhancing early intervention.

The FDA approved epcoritamab plus rituximab and lenalidomide for relapsed or refractory follicular lymphoma indications.

The FDA has granted fast track designation to 4A10 for relapsed/refractory ALL.

The FDA has approved ziftomenib for NPM1-positive acute myeloid leukemia, has accepted a NDA for 177Lu-edotreotide for GEP-NETs, and more.

Ziftomenib has received FDA approval for the treatment of adult patients with relapsed or refractory acute myeloid leukemia harboring an NPM1 mutation.

The FDA granted RMAT designation to MB-105 for CD5-positive relapsed/refractory T-cell lymphoma.

Phase 2 data showed high 2-year survival and deep MRD-negative remissions with a CD22/CD19 CAR T-cell therapy and ASCT “sandwich” approach in B-ALL.

The FDA has approved generic dasatinib tablets for select patients with chronic myeloid leukemia and acute lymphoblastic leukemia.

Pule Wang, MD, discusses safety data with CNS bridging radiotherapy before CAR T in B-cell lymphoma.

Justin Taylor, MD, discusses findings from a study that evaluated the ability of ChatGPT to offer specific information in hematologic malignancies.

The FDA has granted orphan drug designation to M2T-CD33 for the treatment of patients with acute myeloid leukemia.

Belzutifan-based combinations meet end points in RCC, imaging agent under review for SSTR-positive neuroendocrine tumors, and more.

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

Harry P. Erba, MD, PhD; and Jayastu Senapati, MBBS, discuss the effects of drug shortages in hematologic oncology and how to adapt practice when they arise.

Pule Wang, MD, discusses findings from a retrospective study of CNS bridging radiation therapy prior to CAR T-cell therapy in B-cell lymphomas.

The FDA has cleared BVd for multiple myeloma and revumenib for NPM1-mutant AML, and granted priority review to perioperative enfortumab vedotin in MIBC.

The FDA approved revumenib for adult and pediatric patients at least 1 year of age with relapsed or refractory AML with a susceptible NPM1 mutation.

Pule Wang, MD, discusses the design of a retrospective study of CNS bridging radiation therapy prior to CAR T in B-cell lymphomas.

Dr Wang discusses the prevalence of secondary AML, unmet needs for patients with this disease, and how CPX-351 has generated improved outcomes vs 7+3.